Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/66911 |
Resumo: | Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route. |
id |
RCAP_9840954d1b59308665e415c120dbb171 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/66911 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain deliveryCachexiaGhrelinLiposomesNose-to-brainCiências Médicas::Biotecnologia MédicaScience & TechnologyCachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route.Funded by PROSUP/Coordination of Superior Level Staff Improvement (CAPES), University of Sorocaba (UNISO), São Paulo Research Foundation (FAPESP/2014/50928-2), Brazil, granted to MVC, and by the Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE), co-financed by FEDER, under the Partnership Agreement PT2020 granted to EBS (UIDB/04469/2020 (strategic fund)info:eu-repo/semantics/publishedVersionMDPIUniversidade do MinhoT. de Barros, CeciliaRios, Alessandra C.Alves, Thaís F. R.Batain, FernandoCrescencio, Kessi M. M.Lopes, Laura J.Zielinska, AleksandraSeverino, PatriciaG. Mazzola, PriscilaSouto, Eliana B.Chaud, Marco V.20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/66911engT de Barros, C., Rios, A. C., Alves, T. F., et. al. (2020). Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery. International Journal of Molecular Sciences, 21(17), 59741424-67831422-00671661-659610.3390/ijms2117597432825177https://www.mdpi.com/1422-0067/21/17/5974info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:43:18Zoai:repositorium.sdum.uminho.pt:1822/66911Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:40:45.709631Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
title |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
spellingShingle |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery T. de Barros, Cecilia Cachexia Ghrelin Liposomes Nose-to-brain Ciências Médicas::Biotecnologia Médica Science & Technology |
title_short |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
title_full |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
title_fullStr |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
title_full_unstemmed |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
title_sort |
Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery |
author |
T. de Barros, Cecilia |
author_facet |
T. de Barros, Cecilia Rios, Alessandra C. Alves, Thaís F. R. Batain, Fernando Crescencio, Kessi M. M. Lopes, Laura J. Zielinska, Aleksandra Severino, Patricia G. Mazzola, Priscila Souto, Eliana B. Chaud, Marco V. |
author_role |
author |
author2 |
Rios, Alessandra C. Alves, Thaís F. R. Batain, Fernando Crescencio, Kessi M. M. Lopes, Laura J. Zielinska, Aleksandra Severino, Patricia G. Mazzola, Priscila Souto, Eliana B. Chaud, Marco V. |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
T. de Barros, Cecilia Rios, Alessandra C. Alves, Thaís F. R. Batain, Fernando Crescencio, Kessi M. M. Lopes, Laura J. Zielinska, Aleksandra Severino, Patricia G. Mazzola, Priscila Souto, Eliana B. Chaud, Marco V. |
dc.subject.por.fl_str_mv |
Cachexia Ghrelin Liposomes Nose-to-brain Ciências Médicas::Biotecnologia Médica Science & Technology |
topic |
Cachexia Ghrelin Liposomes Nose-to-brain Ciências Médicas::Biotecnologia Médica Science & Technology |
description |
Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/66911 |
url |
http://hdl.handle.net/1822/66911 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
T de Barros, C., Rios, A. C., Alves, T. F., et. al. (2020). Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery. International Journal of Molecular Sciences, 21(17), 5974 1424-6783 1422-0067 1661-6596 10.3390/ijms21175974 32825177 https://www.mdpi.com/1422-0067/21/17/5974 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132954283212800 |